NCT02021942View on ClinicalTrials.gov

Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Primary Inoperable ThymomaLocal Recurrent Thymoma
Interventions
DRUG

SOM230 LAR

SOM230 LAR in a dosage of 60 mg is administered i.m. once every 4 weeks.

Trial Locations (1)

93053

Klinik und Poliklinik für Neurologie der Universität Regensburg, Regensburg

All Listed Sponsors
collaborator

Crolll Gmbh

OTHER

lead

Prof. Dr. Berthold Schalke

OTHER

NCT02021942 - Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size | Biotech Hunter | Biotech Hunter